Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cervel Neurotherapeutics was a clinical-stage medical device company that developed non-invasive brain stimulation technologies for the treatment of psychiatric and neurological disorders. The company's proprietary multi-coil Transcranial Magnetic Stimulation (TMS) platform was designed to enable deeper and more focal stimulation of brain targets compared to traditional TMS devices. Its lead clinical program was focused on Major Depressive Disorder, having completed a Phase 2 study. Cervel was founded as a portfolio company of PureTech Health and received significant backing from New Enterprise Associates. In 2018, VistaGen Therapeutics acquired Cervel's intellectual property and clinical data to complement its own CNS pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cervel Neurotherapeutics.